Aptamer Sciences Inc (KOSDAQ:291650)

South Korea flag South Korea · Delayed Price · Currency is KRW
1,427.00
+22.00 (1.57%)
At close: Mar 9, 2026
50.05%
Market Cap 57.45B
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 40.26M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 381,591
Average Volume 509,722
Open 1,405.00
Previous Close 1,405.00
Day's Range 1,350.00 - 1,447.00
52-Week Range 675.00 - 1,646.00
Beta 0.69
RSI 67.07
Earnings Date n/a

About Aptamer Sciences

Aptamer Sciences Inc, a bio venture company, focuses on the Aptamer technology platform for the development of therapeutic and diagnostic platforms. The company’s platforms include aptamer discovery, optimization, and the development of therapeutics and diagnostics for cancer and neurological disorders. It offers AlloMAp and Bi-Functional Aptame (BiFAp) platform programs for therapeutics, as well as Aptodetect-lung, an early diagnosis kit for lung cancer. Aptamer Sciences Inc was founded in 2011 and is headquartered in Seongnam-si, South Korea. [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2011
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 291650
Full Company Profile

Financial Performance

In 2024, Aptamer Sciences's revenue was 1.08 billion, an increase of 345.26% compared to the previous year's 243.19 million. Losses were -8.70 billion, -36.02% less than in 2023.

Financial Statements

News

There is no news available yet.